ArticleBMC cancer2021

Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.

Qianqian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.